3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
3
Phase 2
2
Phase 1/2
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Thoracic
1
Head & Neck
1
Conditions
Squamous Cell Carcinoma of Head and Neck
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
pembrolizumab
512
Specimen Handling
381
Carboplatin
371
Magnetic Resonance Spectroscopy
333
Cisplatin
327
Nivolumab
302
Cyclophosphamide
295
Radiotherapy
254
Paclitaxel
252
Biopsy
235
Gemcitabine
229
Bevacizumab
212
Dexamethasone
167
durvalumab
162
Oxaliplatin
160
Capecitabine
154
Rituximab
151
Fluorouracil
148
venetoclax
142
atezolizumab
141
Docetaxel
141
Drug Therapy
140
Etoposide
138
Doxorubicin
131
Ipilimumab
125
Radiosurgery
118
Lenalidomide
117
Prednisone
116
Leucovorin
111
fludarabine
109
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Phase 2
×
danvatirsen
×
1 year
×
Clear all
NCT05814666
2026-01-30
PEMDA-HN
Flamingo Therapeutics NV
Phase 2
Terminated
69 enrolled
21 charts
NCT03334617
2025-10-27
HUDSON
AstraZeneca
Phase 2
Active not recruiting
528 enrolled
16 charts